Silexion Therapeutics reprices series E warrants to $0.2603, expects about $0.84M gross proceeds

Silexion Therapeutics Corp

Silexion Therapeutics entered a Sept 28, 2026 inducement letter with holders of 3,216,928 series E warrants to exercise at a reduced $0.2603/share price.
The warrant exercise is expected to raise about $0.84 million gross, before H.C. Wainwright fees; closing is expected on or about Sept 29, 2026.
Silexion will issue Series F and Series G warrants for up to 6,433,856 ordinary shares at $0.2603/share; Series F lasts five years, Series G 24 months after conditions.
H.C. Wainwright & Co. is exclusive placement agent, earning a 7.0% cash fee, 1.0% management fee, and up to 225,185 placement agent warrants at $0.3254/share.
Silexion also cut the exercise price for all outstanding series E warrants covering 3,846,161 ordinary shares to $0.2603/share.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.